[Immunotherapy in head and neck cancer]

Area of Science:

• Oncology
• Immunology
• Head and Neck Cancer Research

Context:

• The immune system's role in recognizing and eliminating malignant cells.
• Mechanisms by which tumors, particularly solid head and neck malignancies, evade immune surveillance.
• Identification of key cellular players like dendritic cells, T lymphocytes, and natural killer cells in anti-tumor immunity.

Purpose:

• To explore the intricate interplay between tumor cells and the host immune system in head and neck cancers.
• To review current and emerging immunotherapeutic strategies targeting tumor-induced immune suppression.
• To highlight the potential of novel agents, including monoclonal antibodies, in cancer treatment.

Summary:

• Tumor cells employ various mechanisms, involving regulatory T cells, myeloid-derived suppressor cells, and cancer-associated fibroblasts, to create an immunosuppressive tumor microenvironment.
• Current research focuses on modulating immune-stimulating and immune-suppressive cytokines, Toll-like receptor activation, and vaccination strategies.
• Monoclonal antibodies targeting immune checkpoint receptors (e.g., PD-1, CTLA-4) and co-stimulatory receptors (e.g., CD28, CD134) are under investigation for their therapeutic efficacy.

Impact:

• Advances in understanding tumor immune evasion pave the way for more effective cancer therapies.
• Novel immunotherapeutics offer new hope for patients with advanced or refractory head and neck cancers.
• Targeting immune checkpoints represents a significant paradigm shift in cancer treatment, with potential for durable responses.